XERS Xeris Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: XERS

Price (delayed)

$1.89

Market cap

$265.46M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.45

Enterprise value

$427.2M

Xeris Pharmaceuticals Inc. is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world.

Highlights
The gross profit has soared by 54% YoY and by 8% from the previous quarter
The company's revenue rose by 49% YoY and by 7% QoQ
XERS's equity has dropped by 115% year-on-year
XERS's quick ratio is down by 44% year-on-year and by 9% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.xerispharma.com
Peers: OMER OMGA

Key stats

What are the main financial stats of XERS
Market
Shares outstanding
140.45M
Market cap
$265.46M
Enterprise value
$427.2M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.61
Earnings
Revenue
$163.91M
EBIT
-$36.9M
EBITDA
-$23.74M
Free cash flow
-$49.29M
Per share
EPS
-$0.45
Free cash flow per share
-$0.36
Book value per share
-$0.05
Revenue per share
$1.19
TBVPS
$1.38
Balance sheet
Total assets
$322.6M
Total liabilities
$329.38M
Debt
$229.19M
Equity
-$6.78M
Working capital
$61.07M
Liquidity
Debt to equity
-33.79
Current ratio
1.64
Quick ratio
1.17
Net debt/EBITDA
-6.81
Margins
EBITDA margin
-14.5%
Gross margin
82.5%
Net margin
-38%
Operating margin
-26.8%
Efficiency
Return on assets
-19.1%
Return on equity
-610.8%
Return on invested capital
-13.7%
Return on capital employed
-16.2%
Return on sales
-22.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

XERS stock price

How has the Xeris Pharmaceuticals stock price performed over time
Intraday
1.61%
1 week
8%
1 month
-9.13%
1 year
-18.18%
YTD
-19.57%
QTD
-14.48%

Financial performance

How have Xeris Pharmaceuticals's revenue and profit performed over time
Revenue
$163.91M
Gross profit
$135.27M
Operating income
-$44.01M
Net income
-$62.26M
Gross margin
82.5%
Net margin
-38%
Xeris Pharmaceuticals's operating margin has soared by 64% YoY and by 17% from the previous quarter
The net margin has soared by 56% YoY and by 6% from the previous quarter
The gross profit has soared by 54% YoY and by 8% from the previous quarter
The company's revenue rose by 49% YoY and by 7% QoQ

Growth

What is Xeris Pharmaceuticals's growth rate over time

Valuation

What is Xeris Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
1.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.61
XERS's EPS is up by 36% year-on-year
XERS's equity has dropped by 115% year-on-year
XERS's price to sales (P/S) is 94% less than its 5-year quarterly average of 26.4 and 21% less than its last 4 quarters average of 2.0
The company's revenue rose by 49% YoY and by 7% QoQ

Efficiency

How efficient is Xeris Pharmaceuticals business performance
XERS's return on equity has dropped by 129% since the previous quarter
The return on invested capital has surged by 73% year-on-year and by 10% since the previous quarter
XERS's ROS has soared by 70% year-on-year and by 12% since the previous quarter
The return on assets rose by 34% year-on-year but it has declined by 2.1% since the previous quarter

Dividends

What is XERS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for XERS.

Financial health

How did Xeris Pharmaceuticals financials performed over time
The total assets is 2.1% less than the total liabilities
XERS's quick ratio is down by 44% year-on-year and by 9% since the previous quarter
XERS's current ratio is down by 35% year-on-year and by 10% since the previous quarter
The debt to equity has plunged by 157% from the previous quarter
XERS's equity has dropped by 115% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.